Use of colostrinin, constituent peptides thereof, and...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C530S300000, C530S350000, C530S324000, C530S326000, C530S327000, C530S328000, C530S334000, C424S535000, C435S007100

Reexamination Certificate

active

07119064

ABSTRACT:
The present invention provides methods that utilize compositions containing colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof, as modulators of intracellular signaling molecules, for example.

REFERENCES:
patent: 4938949 (1990-07-01), Borch
patent: 5595887 (1997-01-01), Coolidge
patent: 6040180 (2000-03-01), Johe
patent: 6410058 (2002-06-01), Gohlke et al.
patent: 6500798 (2002-12-01), Stanton et al.
patent: 6852685 (2005-02-01), Boldogh et al.
patent: 6852700 (2005-02-01), Janusz et al.
patent: 6903068 (2005-06-01), Stanton et al.
patent: 2003/0091606 (2003-05-01), Stanton et al.
patent: 06/041191 (1994-02-01), None
patent: WO 95/00155 (1995-01-01), None
patent: WO 95/30686 (1995-11-01), None
patent: WO 98/14473 (1998-04-01), None
patent: WO 99/65329 (1999-12-01), None
patent: WO 00/75173 (2000-12-01), None
patent: WO 01/11937 (2001-02-01), None
patent: WO 01/12650 (2001-02-01), None
patent: WO 01/12651 (2001-02-01), None
patent: WO 02/13849 (2002-02-01), None
patent: WO 02/13850 (2002-02-01), None
patent: WO 02/13851 (2002-02-01), None
patent: WO 04/37851 (2004-05-01), None
Jurgens et al., “Modification of Human Low-Density Lipoprotein by the Lipid Peroxidation Product 4-Hydroxynonenal,”Biochem Biophys., Jan. 1986;875:103-114.
Janusz et al., “Immunoregulatory properties of synthetic peptides, fragments of a proline-rich polypeptide (PRP) from ovine colostrum,”Molecular Immunology, Oct. 1987;24(10): 1029-1031.
Gage et al., “Isolation, Characterization, and use of Stem Cells from the CNS,”Annu. Rev. Neurosci, 1995;18: 159-92.
Altin et al., “Differential Induction of Primary-response (TIS) Genes in PC12 Pheochromocytoma Cells and the Unresponsive Variant PC12nnr5,”Journal of Biological Chemistry, Mar. 25, 1991;266(9): 5401-5406.
Anneren et al., “GTK, a Src-related Tyrosine Kinase, Induces Nerve Growth Factor-independent Neurite Outgrowth in PC 12 Cells through Activation of the Rap1 Pathway,”Journal of Biological Chemistry, Sep. 15, 2000;275(37): 29153-29161.
Babbit et al.,The Vanderbilt Rubber Handbook, R.T. Vanderbilt Company, Inc., Norwalk, CT., 1978: 344-397.
Bagchi et al., “Comparative in vitro and in vivo protein kinase C activation by selected pesticides and transition metal salts,”Toxicology Letters, 1997;91: 31-37.
Bespalov et al., “Fabs specific for 8-oxoguanine: control of DNA binding,”J. Mol Biol., Nov. 12, 1999;293(5): 1085-95.
Bikfalvi et al., “Biological Roles of Fibroblast Growth Factor-2,”Endocrine Reviews, Feb. 1997;18(1): 26-45.
Blach-Olszewska et al., “Stimulatory effect of ovine colostrinine (a proline-rich polypeptide) on interferons and tumor necrosis factor production by murine resident peritoneal cells,”Ach Immunol Ther Exp(Warsz), 1997;45(1):43-47.
“Blast,” National Institutes of Health [online] Bethesda, M.D. Retrieved from the Internet on May 14, 2001: <URL:http://www.ncbi.nlm.nih.gov/gorf/b12.html>; 1 pg.
Boldogh et al., “Modulation of 4HNE-Mediated Signaling by proline-rich peptides from Ovine Colostrum,”J Mol Neuroscience, May 2003;20(2): 125-134.
Brown et al., “7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque,”J. Lipid Res, 1997;38: 1730-1745.
Bruce-Keller et al., “4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats,”J Neuropathol Exp Neurol, 1998;57: 257-267.
Buescher et al., “Colostral antioxidants: separation and characterization of two activities in human colostrum,”J Pediatr Gastroenterol Nutrl., Jan. 1992;14(1): 47-56.
Buettner, G.R., “The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate,”Arch Biochem Biophys, 1993;300: 535-543.
Cadenas et al., “Mitochondrial free radical generation, oxidative stress, and aging,”Free Radic Biol Med, 2000;29:222-230.
Calingasan et al., “Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease,”J Neurochem. Feb. 1999;72(2):751-6.
Camandola et al., “The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons,”Brain Res Mol Brain Res, 2000;85:53-60.
Chao “Growth factor signaling: where is the specificity?”Cell. Mar. 20, 1992;68(6):995-7.
Chen et al., “Lithium Increase Tyrosine Hydroxylase Levels both In Vivo and In Vitro,”Journal of Neurochemistry, 1998;70(4): 1768-1771.
Cheng et al., “Effects on mGST A4 transfection on 4-hydroxynonenal-mediated apoptosis and differentiation of K562 human erythroleukemia cells,”Arch Biochem Biophys, 1999;372: 29-36.
Cosgaya et al., “Neuronal differentiation of PC12 cells induced by engrailed homeodomain is DNA-binding specific and independent of MAP kinases,”Journal of Cell Science1998; 111: 2377-2384.
Cui et al., “Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells,”Journal of Pharmacology and Experimental Therapeutics, 1997;280(3): 1228-1234.
Dagø et al., “NS 1231, a novel compound with neurotrophic-like effectsin vitroandin vivo,” Journal of Neurochemistry, 2002;81: 17-24.
Davies et al., “Photo-oxidation of proteins and its role in cataractogenesis,”J. Photochem. Photobiol B, 2001;63: 114-125.
Davis et al., “Cellular thiols and reactive oxygen species in drug-induced apoptosis,”J. Pharmacol Exp Ther, 2001;296: 1-6.
DeJongh et al., “Estimation of Systemic Toxicity of Acrylamide by Integration ofin vitroToxicity Data with Kinetic Simulations,”Toxicology and Applied Pharmacology, 1999; 158: 261-268.
DeZwart et al., “Biomarkers of free radical damage applications in experimental animals and in humans,”Free Radic Biol Med, 1999; 26:202-226.
Doye et al., “Phosphorylation of Stathmin and Other Proteins Related to Nerve Growth Factor-induced Regulation of PC12 Cells,”Journal of Biological Chemistry, Jul. 15, 1990;265(20): 11650-11655.
Elgert, “Immunology: Understanding the Immune System,” Text (1996) Wiley-Liss 1stEd. pp. 24-26 and 199-217.
Esterbauer et al., “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,”Free Radic Biol Med. 1991;11(1):81-128.
Evan et al., “A matter of life and cell death,”Science, 1998; 281: 1317-1322.
Feng et al., “NF-κB/Rel Proteins are Required for Neuronal Differentiation of SH-SY5Y Neuroblastoma Cells,”Journal of Biological Chemistry, Oct. 22, 1999;274(43): 30341-30344.
Fields et al.,Synthetic Peptides: A User's Guide, W.M. Freeman & Company, New York, NY, pp. 77-183 (1992).
Fillmore et al., “Differentiation of PC12 cells with nerve growth factor is associated with induction of transin synthesis and release,”J Neurosci Res. Apr. 1992;31(4):662-9.
Finkel et al., “Oxidants, oxidative stress and the biology of ageing,”Science, 1998;281: 1317-1322.
Friguet et al., “Protein degradation by the proteasome and its implications in aging,”Ann N Y Acad Sci, 2000;908: 143-154.
Gabbita et al., “Increased nuclear DNA oxidation in the brain in Alzheimer's disease,”J Neurochem. Nov. 1998;71(5):2034-40.
Gabbita et al., “Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain,”J Neurochem. Oct. 1999;73(4):1660-6.
Gardner et al., “Development of a peptide antibody specific to human glutathione S-transferase alpha 4—4 (hGSTA4—4) reveals preferential localization in human liver mitochondria,”Arch Biochem Biophys, 2001;390: 19-27.
Good et al., “Evidence of neuronal oxidative damage in Alzheimer's disease,”Am J Pathol. Jul. 1996;149(1):21-8.
Gratama et al., “

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Use of colostrinin, constituent peptides thereof, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of colostrinin, constituent peptides thereof, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of colostrinin, constituent peptides thereof, and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3666957

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.